Take Homes in Ovarian Cancer
Take Homes in Ovarian Cancer
Source/Disclosures
Source:

Matulonis UA, et al. Abstract 6005. Presented at: ASCO20 Virtual Scientific Program; May 29-31, 2020.


Disclosures: Matulonis reports receiving honoraria from Advaxis; serving in a consulting or advisory role for Immunogen, Merck and Novartis; receiving research funding from Fujifilm, Immunogen, Leap Therapeutics, Merck, Mersana, Novartis, SQZ Biotechnologies, Syndax and Tesaro; and receiving travel, accommodations or expenses from AstraZeneca.

July 01, 2020
1 min watch
Save

Pembrolizumab shows modest, durable response in recurrent ovarian cancer

Source/Disclosures
Source:

Matulonis UA, et al. Abstract 6005. Presented at: ASCO20 Virtual Scientific Program; May 29-31, 2020.


Disclosures: Matulonis reports receiving honoraria from Advaxis; serving in a consulting or advisory role for Immunogen, Merck and Novartis; receiving research funding from Fujifilm, Immunogen, Leap Therapeutics, Merck, Mersana, Novartis, SQZ Biotechnologies, Syndax and Tesaro; and receiving travel, accommodations or expenses from AstraZeneca.

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

In the KEYNOTE-100 study, presented during the ASCO2020 Virtual Scientific Program, Ursula A. Matulonis, MD, of Dana Farber Cancer Institute, showed pembrolizumab had a modest but durable impact on recurrent ovarian cancer.

“Pembrolizumab like other single-agent immune checkpoint inhibitors which have been studied in recurrent ovarian cancer, has modest activity in recurrent ovarian cancer. The activity of pembrolizumab appears to be higher in cancers that were CPS higher,” she told Healio. “The median duration of response – if there is a response it’s actually a pretty long response – 10.2 months.”

PDL-1 expression did seem to indicate the response rate, Matulonis said. Higher expression levels dictated greater response rate, which she said was similar to other KEYNOTE study results.